Your browser doesn't support javascript.
loading
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.
Bolis, Marco; Bossi, Daniela; Vallerga, Arianna; Ceserani, Valentina; Cavalli, Manuela; Impellizzieri, Daniela; Di Rito, Laura; Zoni, Eugenio; Mosole, Simone; Elia, Angela Rita; Rinaldi, Andrea; Pereira Mestre, Ricardo; D'Antonio, Eugenia; Ferrari, Matteo; Stoffel, Flavio; Jermini, Fernando; Gillessen, Silke; Bubendorf, Lukas; Schraml, Peter; Calcinotto, Arianna; Corey, Eva; Moch, Holger; Spahn, Martin; Thalmann, George; Kruithof-de Julio, Marianna; Rubin, Mark A; Theurillat, Jean-Philippe P.
Afiliação
  • Bolis M; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland. marco.bolis@ior.usi.ch.
  • Bossi D; Computational Oncology Unit, Department of Oncology, Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS, 20156, Milano, Italy. marco.bolis@ior.usi.ch.
  • Vallerga A; Bioinformatics Core Unit, Swiss Institute of Bioinformatics, TI, 6500, Bellinzona, Switzerland. marco.bolis@ior.usi.ch.
  • Ceserani V; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Cavalli M; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Impellizzieri D; Bioinformatics Core Unit, Swiss Institute of Bioinformatics, TI, 6500, Bellinzona, Switzerland.
  • Di Rito L; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Zoni E; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Mosole S; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Elia AR; Computational Oncology Unit, Department of Oncology, Istituto di Richerche Farmacologiche 'Mario Negri' IRCCS, 20156, Milano, Italy.
  • Rinaldi A; Department of Biomedical Research, University of Bern, 3008, Bern, Switzerland.
  • Pereira Mestre R; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • D'Antonio E; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Ferrari M; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Stoffel F; Oncology Institute of Southern Switzerland, Bellinzona, TI, 6500, Switzerland.
  • Jermini F; Oncology Institute of Southern Switzerland, Bellinzona, TI, 6500, Switzerland.
  • Gillessen S; Urology Department, Ente Ospedaliero Cantonale, Bellinzona, TI, Switzerland.
  • Bubendorf L; Urology Department, Ente Ospedaliero Cantonale, Bellinzona, TI, Switzerland.
  • Schraml P; Urology Department, Ente Ospedaliero Cantonale, Bellinzona, TI, Switzerland.
  • Calcinotto A; Oncology Institute of Southern Switzerland, Bellinzona, TI, 6500, Switzerland.
  • Corey E; Faculty of Biomedical Sciences, University of Southern Switzerland (USI), TI, 6900, Lugano, Switzerland.
  • Moch H; Institute of Surgical Pathology, University Hospital Basel, 4031, Basel, Switzerland.
  • Spahn M; Department of Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.
  • Thalmann G; Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, TI, 6500, Switzerland.
  • Kruithof-de Julio M; Department of Urology, University of Washington, Seattle, WA, 98195, USA.
  • Rubin MA; Department of Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.
  • Theurillat JP; Lindenhofspital Bern, Prostate Center Bern, 3012, Bern, Switzerland.
Nat Commun ; 12(1): 7033, 2021 12 02.
Article em En | MEDLINE | ID: mdl-34857732
ABSTRACT
Comprehensive genomic studies have delineated key driver mutations linked to disease progression for most cancers. However, corresponding transcriptional changes remain largely elusive because of the bias associated with cross-study analysis. Here, we overcome these hurdles and generate a comprehensive prostate cancer transcriptome atlas that describes the roadmap to tumor progression in a qualitative and quantitative manner. Most cancers follow a uniform trajectory characterized by upregulation of polycomb-repressive-complex-2, G2-M checkpoints, and M2 macrophage polarization. Using patient-derived xenograft models, we functionally validate our observations and add single-cell resolution. Thereby, we show that tumor progression occurs through transcriptional adaption rather than a selection of pre-existing cancer cell clusters. Moreover, we determine at the single-cell level how inhibition of EZH2 - the top upregulated gene along the trajectory - reverts tumor progression and macrophage polarization. Finally, a user-friendly web-resource is provided enabling the investigation of dynamic transcriptional perturbations linked to disease progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Transcriptoma / Proteína Potenciadora do Homólogo 2 de Zeste / Proteínas de Neoplasias Tipo de estudo: Qualitative_research Limite: Animals / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Transcriptoma / Proteína Potenciadora do Homólogo 2 de Zeste / Proteínas de Neoplasias Tipo de estudo: Qualitative_research Limite: Animals / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça
...